New Enterprise Associates's Life Science Portfolio

Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.

Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.

Pathos is a biotechnology company that leverages AI to accelerate oncology drug development.

Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.

Nexo Therapeutics offers treatments for some of cancer's most intractable targets.

Launchpad Therapeutics operates as an antibody-focused precision oncology company.

Reltio powers real-time data intelligence and AI transformation with enterprise-grade security and governance.

Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with rare and prevalent diseases.

Resilience is a biomanufacturing company that provides access to complex medicines and protects biopharmaceutical supply chains.

Charm Therapeutics designs and develops small-molecule therapeutics that target the interaction between menin and the KMT2A protein.